A new alternative in treating short bowel syndromeOctober 10, 2008
SBS is a clinical condition characterized by diarrhea, dehydration, electrolyte imbalance, malabsorption, and progressive malnutrition related to a wide resection of the small intestine. The most important therapeutic objectives in the management of SBS are maintenance the patient's calorie intake and nutritional status. However, some enteral nutrition (EN) products use for energy supports in order to reduce total parenteral nutrition (TPN) demand. The new treatment modalities alternate the current ones are still under research with the experimental and clinical studies. Chlorella is a species of green algae that grows in fresh water. It has been consumed as a food source for centuries in mainly Japan and other Far East countries, besides, it's healing properties has enhanced it's consumption too. Several EN products have been used for SBS.
A research article to be published on July 28, 2008 in the World Journal of Gastroenterology addresses this question. The research team was led by Mustafa Kerem from Gazi University Experimental Surgery Center. In this original study, it has been seen that there's a positive effect of chlorella crude extract (CCE) on intestinal adaptation of rats which had undergone short bowel syndrome. Administration of CCE lead significant increase in intestinal villi height and villi width, intestinal protein and DNA amount, and serum citruline levels which is a sign of improved intestinal absorption. As being the first it's an important study. By this information algs which are easily found widely in salt and fresh waters and can be generated easily, can be used in clinical settings.
CCE has beneficial role in intestinal adaptation. It seems that it can be an alternative to the other commercial enteral and parenteral products.
-end-Reference: Kerem M, Salman B, Pasaoglu H, Bedirli A, Alper M, Katircioglu H, Atici T, Perçin EF, Ofluoglu E. Effects of microalgea chlorella species crude extracts on intestinal adaptation in the experimental short bowel syndrome. World J Gastroenterol 2008; 14(28): 4512-4517 http://www.wjgnet.com/1007-9327/14/4512.asp
Correspondence to: Mustafa Kerem, MD, Department of General Surgery, Faculty of Medicine, Gazi University, Besevler 06510, Ankara, Turkey. firstname.lastname@example.org Telephone: +90-312-2025727 Fax: +90-312-2124647
About World Journal of Gastroenterology
World Journal of Gastroenterology (WJG), a leading international journal in gastroenterology and hepatology, has established a reputation for publishing first class research on esophageal cancer, gastric cancer, liver cancer, viral hepatitis, colorectal cancer, and H pylori infection and provides a forum for both clinicians and scientists. WJG has been indexed and abstracted in Current Contents/Clinical Medicine, Science Citation Index Expanded (also known as SciSearch) and Journal Citation Reports/Science Edition, Index Medicus, MEDLINE and PubMed, Chemical Abstracts, EMBASE/Excerpta Medica, Abstracts Journals, Nature Clinical Practice Gastroenterology and Hepatology, CAB Abstracts and Global Health. ISI JCR 2003-2000 IF: 3.318, 2.532, 1.445 and 0.993. WJG is a weekly journal published by WJG Press. The publication dates are the 7th, 14th, 21st, and 28th day of every month. WJG is supported by The National Natural Science Foundation of China, No. 30224801 and No. 30424812, and was founded with the name of China National Journal of New Gastroenterology on October 1, 1995, and renamed WJG on January 25, 1998.
About The WJG Press
The WJG Press mainly publishes World Journal of Gastroenterology.
World Journal of Gastroenterology
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.